Supranutritional selenium suppresses ROS-induced generation of RANKL-expressing osteoclastogenic CD4+ T cells and ameliorates rheumatoid arthritis.
Jiahuan QinXia HuangNaiqi WangPengcheng ZhouHao ZhangZhian ChenKaili LiangDongcheng GongQunxiong ZengPeng NiuAnping ChenLin YuanZhaohui YangLinchong SuNan ShenJun DengDi YuPublished in: Clinical & translational immunology (2021)
Supranutritional Se suppresses RANKL-expressing osteoclastogenic CD4+ T cells and could be beneficial to RA, which warrants formal testing in randomised clinical trials.
Keyphrases
- clinical trial
- rheumatoid arthritis
- disease activity
- signaling pathway
- open label
- nuclear factor
- high glucose
- bone loss
- ankylosing spondylitis
- double blind
- diabetic rats
- phase ii
- dna damage
- interstitial lung disease
- cell death
- study protocol
- reactive oxygen species
- systemic lupus erythematosus
- mouse model
- oxidative stress
- endothelial cells
- phase iii
- randomized controlled trial
- toll like receptor
- wild type